RxDoctor Payments Data

Kasi Novak

Nurse Practitioner · Rolling Meadows, ILNPI 1649762550

Payments from drug & device makers

$8,209in general payments, 2019–2025

Across 377 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$516
  • Johnson & Johnson$492
  • Lilly USA, LLC$466
  • AstraZeneca$392
  • Seagen Inc.$344
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,98297%
  • Education$2283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,209 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$88,221
Medicare patients
38
Services billed
3,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TukysaTucatinib13$339,850
CalquenceAcalabrutinib Maleate22$336,335
IbrancePalbociclib16$246,552
KisqaliRibociclib Succinate11$182,867
XareltoRivaroxaban27$32,262
EliquisApixaban32$23,229
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$4,467
Exemestane14$1,308
Betamethasone Dipropionate12$1,006
Lidocaine13$896
Ondansetron OdtOndansetron24$604
Anastrozole39$524
Hydroxyurea19$394
Oxycodone Hcl20$354
Duloxetine Hcl11$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Seagen Inc.Tukysa$344$339,85013 claims
AstraZenecaCalquence$392$336,33522 claims
PfizerIbrance, Eliquis$94$269,78148 claims
NovartisKisqali$1,165$182,86711 claims
Johnson & JohnsonXarelto$492$32,26227 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$30318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Rolling Meadows

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →